Very early molecular responses in the first two months of therapy are highly predictive of deep molecular responses at 18 months, in chronic myeloid leukemia patients treated upfront with nilotinib
Services
Services
Date issued
2014Journal title
Haematologica
Type of content
Publicación de congreso
